Imperia P S, Lazarus H M, Lass J H
Division of Ophthalmology, University Hospitals of Cleveland, Ohio.
Surv Ophthalmol. 1989 Nov-Dec;34(3):209-30. doi: 10.1016/0039-6257(89)90105-7.
Cancer chemotherapy has changed rapidly in recent years. New agents are constantly being developed. Established agents are being used with increased frequency, in new combinations, at higher dosages, and via new routes of administration. Enhanced survival, as well as increased drug toxicity, has resulted. Ocular toxicity is not uncommon and can greatly impact on quality of life. Practitioners in all fields are increasingly caring for patients who are receiving cancer chemotherapy. The recognition of eye disease resulting from chemotherapy is essential to appropriate patient management. We provide a review of the rapidly growing body of literature on the ocular toxicity of systemic cancer chemotherapy with particular attention to context, clinical course, mechanism, prevention and treatment.
近年来，癌症化疗发展迅速。新的化疗药物不断研发出来。已有的药物正以更高的频率、新的组合方式、更高的剂量以及通过新的给药途径使用。这带来了生存率的提高，但同时药物毒性也增加了。眼部毒性并不罕见，并且会对生活质量产生重大影响。各个领域的从业者越来越多地护理正在接受癌症化疗的患者。认识到化疗引起的眼部疾病对于恰当的患者管理至关重要。我们对关于全身性癌症化疗眼部毒性的快速增长的文献进行综述，特别关注背景、临床病程、机制、预防和治疗。
